CV2001: SARS-CoV-2 3CL Protease

LifeSensors CV2001 is a SARS-CoV-2 3CL protease, a key antiviral drug target with unique cleavage specificity, essential for COVID-19 research and drug discovery

$829.00

SKU CV-2001-0100 Categories DUBs, Viral and Bacterial DUBs

In stock

Product Advantages

Applications

In Vitro 3CL Protease Inhibitor Screening

Background

Within the last two decades, SARS and MERS coronaviruses emerged as global health concerns causing severe acute respiratory syndromes. In December 2019, a novel coronavirus (SARS-CoV-2) was identified in Wuhan, Hubei province in China. The SARS-CoV genome encodes several enzymes including chymotrypsin-like protease (CLPro; 3CLp). This key enzyme along with PLPro play a crucial role by processing a large viral polypeptide (polyprotein 1ab) into functional enzymes. This process is essential for the replication of the virus. SARS-CoV-2 3CLPro shares a 96% identity in protein sequence with 3CLPro from SARS-CoV. It recognizes a unique cleavage site Leu-Gln↓(Ser, Ala, Gly) at no less than 11 sites on the large polyprotein 1ab. The 3CLPro represents an ideal antiviral drug target for counteracting SARS-CoV-2 infection as no human protease is known to share the same cleavage specificity.

Info

Species	SARS-CoV-2
Source	E. coli
Tag	None
Molecular Weight	34 kDa
Quantity	100 µg
Concentration	Variable
Formulation	50 mM Tris-HCl pH 8.5, 150 mM NaCl, 1 mM DTT, 10% glycerol
Storage	-80^o C. Avoid repeated freeze/thaw cycles.